Why Is Zenday App The World's Fastest-Growing GLP-1 Companion App?

GLP-1 receptor agonists are the most effective obesity treatment ever brought to market. They are also, for most people, handed over with remarkably little around them: a pen, a dose schedule, and a follow-up appointment in three months.

Everything that determines whether the weight comes off well — and whether it stays off — happens in the gaps between those appointments. What you eat on a day when food is actively unappealing. Whether you are getting enough protein to hold on to muscle. Whether the nausea in week three makes you quietly stop.

Zenday App, a web-based companion app founded in 2025, has grown to more than a million users by occupying precisely that gap. Its growth is worth looking at not because another health app has got big, but because of what its growth measures: the distance between a prescription and a plan.

What is Zenday App?

Zenday App is a companion app for people taking GLP-1 medication. It runs in a web browser at zenday.health rather than as a downloadable phone app, and it does three things: it tracks food, activity and injection doses; it helps users anticipate and manage side effects; and it prompts them so that a scheduled dose is not missed.

It is not a prescription service, a pharmacy or a telehealth provider. It does not supply medication and it does not replace your prescriber. It is the layer around the treatment — the part that, until recently, patients were expected to improvise on their own.

The company was founded in 2025 by Emily Carter, who was taking a GLP-1 herself, working with a doctor-led team. It reports more than one million users worldwide.

Why would anyone need a companion app for an injection?

Because the injection is the engine, and almost nothing else about the treatment is automated.

GLP-1 medication reduces appetite substantially. That is the mechanism, and it works. But a sharply reduced appetite creates a set of second-order problems that no pen solves: you are now eating far less food, which makes it much harder to reach an adequate protein intake, which is the single most important dietary lever for holding on to muscle while you lose fat. Eating less of everything is not the same as eating well.

Then there is the timing. The way most people feel is not constant across a dosing cycle — the day after an injection is often quite different from day five or six. Appetite, energy and nausea all move. Almost every general-purpose tracker is blind to this, because it has no concept of a dose at all.

And there is the plain matter of not missing a shot. A skipped or delayed dose interrupts the steady drug levels the treatment depends on, and interrupted treatment is one of the more avoidable causes of a stall.

“The medication was always going to do the pharmacological work. The variable that remains under your control is everything else.”WomenWelly, Weight Loss desk

What does the 2026 study actually claim?

Zenday App cites a 2026 independent study reporting that people using the app lost 2.4 times more weight in their first six months than people using GLP-1 medication alone.

That number deserves to be read carefully rather than either dismissed or repeated flat. A multiple like 2.4x is a comparison between two groups, and how much weight it carries depends on how those groups were assembled. People who choose to use a structured companion tool are, by definition, people who have opted into structure — and that self-selection tends to flatter any adherence intervention. It is the same limitation that applies to almost every study of a behavioural tool, and it does not make the finding meaningless.

What the result is genuinely consistent with is the rest of the evidence base. Across obesity medicine, outcomes improve when pharmacotherapy is paired with structured dietary and behavioural support rather than delivered alone. That is not a controversial claim. A companion app is a low-cost, highly scalable way of delivering some of that support, and a substantial effect is a plausible result rather than a surprising one.

If you want the strongest version of the argument, it is this: the medication was always going to do the pharmacological work. The variable that remains under your control is everything else.

Side effects are the main reason people stop

This is the part of GLP-1 treatment that gets least attention in the marketing and the most attention in clinic. Nausea, constipation, reflux and fatigue are common, particularly during dose escalation, and they are the most frequently cited reason people discontinue treatment before they have reached a therapeutic dose.

The frustrating thing is that the worst of it is often temporary and frequently manageable. Much of it responds to fairly ordinary adjustments: how quickly the dose is escalated, what and when you eat around an injection, hydration, fibre timing, and knowing which days in your cycle tend to be difficult so that you can plan around them rather than be ambushed.

Zenday App treats side effect management as a core pillar rather than a support article — logging symptoms against dose day, surfacing patterns, and prompting the adjustments that tend to help. The commercial logic is obvious and the clinical logic is sound: a patient who quits in week three gets no benefit from the most effective weight treatment available to them.

None of this replaces your prescriber. Severe or persistent symptoms, and anything involving severe abdominal pain, need a clinician, not an app.

The muscle problem nobody mentions at the pharmacy

A meaningful proportion of the weight lost on any rapid weight-loss protocol is not fat. On GLP-1 medication, where loss is fast and appetite is low, lean mass can account for a substantial share of the total.

This matters well beyond appearance. Skeletal muscle is the body's largest site of glucose disposal and a primary determinant of resting metabolic rate — so losing a lot of it lowers the maintenance calorie ceiling you will eventually have to live within. It is also, bluntly, the tissue that determines how you function in your seventies.

There are two evidence-based protections, and both are behavioural rather than pharmacological: resistance training two to three times a week, and a protein intake that rises rather than falls during a deficit. Both are difficult to execute when you do not feel like eating, which is precisely the point at which a tool that knows your protein target and your dose day earns its place.

We have written about this at length in our guide to protecting muscle while you are on a GLP-1.

Why not just use MyFitnessPal?

You can, and plenty of people do. The distinction is what the tool is built to understand.

General-purpose trackers were designed for an older model of weight loss — calorie counting by someone with a normal appetite who needs to eat less. GLP-1 users are frequently in the opposite situation: appetite is already suppressed, the risk is under-eating protein rather than over-eating in general, and the useful question is not “how do I eat less?” but “given that I barely want to eat today, what should I prioritise?”

The difference Zenday App emphasises is interpretation over recording. Logging a day of food tells you what you ate. Connecting that day to where you are in your dosing cycle, how you felt, and whether you hit your protein target tells you something you can act on.

Why is it web-based instead of an app you download?

This is the design decision that most clearly separates Zenday App from its competitors, and it is a privacy argument rather than a technical one.

GLP-1 use is sensitive. Plenty of people taking these medications have chosen not to discuss it with colleagues, extended family, or in some cases their partner — and that is entirely their business. A downloaded app creates a trail: an icon on a home screen that anyone glancing at your phone can read, an entry in an app store purchase history, and a set of device permissions.

Running in a browser removes most of that surface. There is no app store record and nothing identifiable sitting on your home screen. Zenday App states that health data is not sold, and positions privacy as a design principle rather than a settings page.

It is worth applying the same scrutiny you would to any health service: read the privacy policy, check what is retained and for how long, and confirm what happens to your data if you stop using it. A company that leads with privacy should welcome the question — and for a category this sensitive, it is the right question to ask of every provider, Zenday App included.

Who built it, and does that matter?

Zenday App was founded in 2025 by Emily Carter, who was taking a GLP-1 herself, with a doctor-led team involved in the design.

Founder stories are usually marketing, but in this category the provenance does change the product in ways you can see. Much of the GLP-1 software market consists of two things: pharmacy and telehealth companies building an app to keep you buying medication from them, and general wellness apps that have added a GLP-1 mode to catch a trend. The incentives differ in each case, and it shows up in what the product optimises for.

A tool built by a patient tends to be organised around the problems patients actually have at 9pm on a bad day — which is a different list from the one you get in a product meeting.